Jade Biosciences, Inc. (JBIO) Current Ratio
- Current ratio · latest quarter: Value 14.93×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 14.93× | Current assets / current liabilities. $471.25M ÷ $31.57M ≈ 14.93× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 471.25M USD | Assets, Current |
| Current obligations | 31.57M USD | Liabilities, Current |
| Cash and equivalents | 107.25M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 6.58M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $471.25M | $31.57M | $107.25M | (m) | (m) | (m) | $6.58M | (m) | 14.93× |
| 2026-03-31 | $318.52M | $22.29M | $55.09M | (m) | (m) | (m) | $3.98M | (m) | 14.29× |
| 2025-12-31 | $348.82M | $16.54M | $88.44M | (m) | (m) | (m) | $2.15M | (m) | 21.09× |
| 2025-09-30 | $201.36M | $22.36M | $50.11M | (m) | (m) | (m) | $1.35M | (m) | 9.01× |
| 2025-06-30 | $222.98M | $21.62M | $220.94M | (m) | (m) | (m) | $7.59M | (m) | 10.31× |
| 2025-03-31 | $77.37M | $2.42M | $44.22M | (m) | (m) | (m) | $69.00K | (m) | 32.01× |
| 2024-12-31 | $69.65M | $12.00M | $69.39M | (m) | (m) | (m) | $1.29M | (m) | 5.81× |
| 2024-09-30 | $90.61M | $10.31M | $31.11M | (m) | (m) | (m) | $908.00K | (m) | 8.78× |
| 2024-06-30 | $110.76M | $17.02M | $31.07M | (m) | (m) | (m) | $4.18M | (m) | 6.51× |
| 2024-03-31 | $103.24M | $15.52M | $9.12M | (m) | (m) | (m) | $3.31M | (m) | 6.65× |
| 2023-12-31 | $124.23M | $17.64M | $23.49M | (m) | (m) | (m) | $2.40M | (m) | 7.04× |
| 2023-09-30 | $137.60M | $14.72M | $32.18M | (m) | (m) | (m) | $3.50M | (m) | 9.34× |
| 2023-06-30 | $152.47M | $13.28M | $60.90M | (m) | (m) | (m) | $5.53M | (m) | 11.48× |
| 2023-03-31 | $120.57M | $10.64M | $26.57M | (m) | (m) | (m) | $4.73M | (m) | 11.33× |
| 2022-12-31 | $131.50M | $7.78M | $22.40M | (m) | (m) | (m) | $2.58M | (m) | 16.90× |
| 2022-09-30 | $145.16M | $7.71M | $22.42M | (m) | (m) | (m) | $4.54M | (m) | 18.84× |
| 2022-06-30 | $153.45M | $3.76M | $27.46M | (m) | (m) | (m) | $2.07M | (m) | 40.85× |
| 2022-03-31 | $165.88M | $4.70M | $28.14M | (m) | (m) | (m) | $2.86M | (m) | 35.27× |
| 2021-12-31 | $174.33M | $2.55M | $54.20M | (m) | (m) | (m) | $1.21M | (m) | 68.37× |
| 2021-09-30 | $183.10M | $3.83M | $180.88M | (m) | (m) | (m) | $2.56M | (m) | 47.87× |
| 2021-06-30 | $59.31M | $4.19M | $59.15M | (m) | (m) | (m) | (m) | (m) | 14.14× |
| 2020-12-31 | $4.68M | $1.77M | $4.57M | (m) | (m) | (m) | $618.00K | (m) | 2.64× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |